About mitnewdigs

This author has not yet filled in any details.
So far mitnewdigs has created 11 blog entries.

AI and machine learning key enablers of healthcare value, expert panel says

MIT NEWDIGS Director and advisor speak at LIGHT Forum on AI in Healthcare

CAMBRIDGE, MASSACHUSETTS—MIT NEW Drug Development ParadIGmS (NEWDIGS) director Dr Gigi Hirsch, and program advisor R. John Glasspool spoke this week at the inaugural Leaders in Global Health & Technology (LIGHT) Forum hosted by Stanford Medical School in California. NEWDIGS is an international “think […]

MIT NEWDIGS Hosts Design Lab on New Gene and Oncology Therapy Financing Models

Industry leaders, patient advocates, policymakers collaborate to lower barriers to potentially curative treatments

CAMBRIDGE, MASSACHUSETTS—The MIT NEW Drug Development ParadIGmS (NEWDIGS) initiative, an international biomedical innovation “think and do tank” involving a range of stakeholders in the healthcare system, hosted a collaborative Design Lab to explore ways to make potentially curative—but expensive—therapies available to patients as […]

Dr Gigi Hirsch and John Glasspool to speak at LIGHT Forum

MIT NEWDIGS director Dr Gigi Hirsch and her colleague R. John Glasspool will address the LIGHT Forum on the impact of artificial intelligence and Big Data on healthcare. They will explore the evolution from an emphasis on efficacy to a focus on value, and how all healthcare stakeholders can collaborate to improve outcomes for all […]

Hilary Malone joins MIT NEWDIGS Executive Committee

Regulatory and business leader will help accelerate system-wide biomedical innovation

Dr Hilary MaloneCAMBRIDGE, MASSACHUSETTS, 1 MARCH 2017—The MIT New Drug Development Paradigms Initiative (NEWDIGS) announced today that Hilary Malone, Chief Regulatory Officer for pharmaceutical company Sanofi, has joined the NEWDIGS Executive Committee. Sanofi is a strategic partner of […]

MIT NEWDIGS Hosts Design Lab on Clinical Trial Innovation

Biomedical Innovation Initiative Supporting New NIH-Funded Trial Innovation Center

CAMBRIDGE, MASSACHUSETTS—The MIT NEW Drug Development ParadIGmS (NEWDIGS) initiative, an international biomedical innovation “think and do tank”, co-hosted an “Efficacy to Effectiveness Clinical Trial” Design Lab in partnership with the Tufts Clinical Translational Science Institute (CTSI) and the new Johns Hopkins University (JHU) – Tufts Medical Center […]

Kay Larholt joins MIT NEWDIGS as Director of Integrated Knowledge Solutions

Industry veteran will lead development of new decision support technologies

CAMBRIDGE, MASSACHUSETTS—The MIT New Drug Development Paradigms Initiative (NEWDIGS) announced today the hire of Dr. Kay M. Larholt as their Director of Integrated Knowledge Solutions. Dr. Larholt will lead a portfolio of activities focused on “Knowledge Generation and Use 2.0,” a critical component of Adaptive Biomedical […]

EVENT REPORT: MIT’s NEWDIGS Launches New Program in Healthcare Data

Data program focuses on facilitating the coordinated evolution of global data systems to more effectively reduce uncertainty in drug development and clinical decision-making.

The New Drug Development Paradigms Program (NEWDIGS) of the MIT Center for Biomedical Innovation has launched a program focused on driving greater value from healthcare data for patients, regulators, payers, and physicians. The […]

MIT’s NEWDIGS Launches New Program in Healthcare Data

The inaugural meeting of the NEWDIGS Data Program was held in January 2015, and brought together international experts from academia, government, information technology, and the healthcare sector. A series of panel discussions focused on identifying the gaps and opportunities that might be addressed through better international cooperation in data system design and use. Through discussion, […]

NEWDIGS 2015 Data Program Workshop

By invitation only
January 14-15, 2015


Adaptive pathways: a future approach to bring new medicines to patients?

December 12th, 2014

Scientists argue that scientific and political changes will make adaptive pathways the preferred approach to make new treatments available. “Adaptive pathways should be the preferred approach in the near future to bring new medicines to patients.” A number of scientists, including members of the European Medicines Agency (EMA) and its scientific Committees take this position in a co-authored article published in Clinical Pharmacology and Therapeutics.